UCMA

Summary

UCMA (upper zone of growth plate and cartilage matrix associated, HGNC:25205) is a protein-coding gene on chromosome 10p13, encoding Unique cartilage matrix-associated protein (Q8WVF2). May be involved in the negative control of osteogenic differentiation of osteochondrogenic precursor cells in peripheral zones of fetal cartilage and at the cartilage-bone interface.

This gene encodes a chondrocyte-specific, highly charged protein that is abundantly expressed in the upper immature zone of fetal and juvenile epiphyseal cartilage. The encoded protein undergoes proteolytic processing to generate a mature protein that is secreted into the extracellular matrix. The glutamic acid residues in the encoded protein undergo gamma carboxylation in a vitamin K-dependent manner. Undercarboxylation of the encoded protein is associated with osteoarthritis in humans. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 221044 — RefSeq curated summary.

At a glance

• GWAS associations: 18
• Clinical variants (ClinVar): 54 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_145314

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25205
Approved symbol	UCMA
Name	upper zone of growth plate and cartilage matrix associated
Location	10p13
Locus type	gene with protein product
Status	Approved
Aliases	GRP
Ensembl gene	ENSG00000165623
Ensembl biotype	protein_coding
Entrez	221044

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000378681, ENST00000463405, ENST00000914827, ENST00000914828

RefSeq mRNA: 3 — MANE Select: NM_145314 NM_001303118, NM_001303119, NM_145314

CCDS: CCDS31147

Canonical transcript exons

ENST00000378681 — 5 exons

Exon	Start	End
ENSE00001155893	13233735	13233800
ENSE00001478405	13234201	13234374
ENSE00003277151	13229611	13229709
ENSE00003455053	13233538	13233633
ENSE00003843116	13221766	13222200

Expression profiles

Bgee: expression breadth broad, 55 present calls, max score 95.53.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0859 / max 66.5521, expressed in 27 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
108293	0.0329	14
108294	0.0312	7
108292	0.0218	5

Top tissues by expression

228 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cartilage tissue	UBERON:0002418	95.53	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	93.92	gold quality
oocyte	CL:0000023	89.33	gold quality
secondary oocyte	CL:0000655	81.95	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	77.01	silver quality
pancreatic ductal cell	CL:0002079	76.17	silver quality
upper arm skin	UBERON:0004263	70.54	gold quality
ileal mucosa	UBERON:0000331	68.13	silver quality
tibia	UBERON:0000979	66.69	gold quality
tibialis anterior	UBERON:0001385	61.78	silver quality
amniotic fluid	UBERON:0000173	59.95	gold quality
epithelial cell of pancreas	CL:0000083	56.61	gold quality
deltoid	UBERON:0001476	55.40	gold quality
cardiac muscle of right atrium	UBERON:0003379	54.34	gold quality
left ventricle myocardium	UBERON:0006566	54.23	gold quality
apex of heart	UBERON:0002098	53.96	gold quality
kidney epithelium	UBERON:0004819	53.93	gold quality
trachea	UBERON:0003126	53.73	silver quality
nasal cavity epithelium	UBERON:0005384	52.83	gold quality
amygdala	UBERON:0001876	52.79	gold quality
myocardium	UBERON:0002349	50.25	gold quality
quadriceps femoris	UBERON:0001377	47.73	gold quality
temporal lobe	UBERON:0001871	47.22	gold quality
pituitary gland	UBERON:0000007	46.88	gold quality
vastus lateralis	UBERON:0001379	45.54	gold quality
adenohypophysis	UBERON:0002196	43.72	gold quality
layer of synovial tissue	UBERON:0007616	43.55	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
nipple	UBERON:0002030	43.32	gold quality
skeletal muscle tissue	UBERON:0001134	43.07	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.30

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RBPJ

miRNA regulators (miRDB)

15 targeting UCMA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-4527	99.66	67.43	714
HSA-MIR-6757-3P	99.63	66.88	1089
HSA-MIR-6503-5P	99.62	66.96	597
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-377-3P	99.37	70.18	1905
HSA-MIR-7854-3P	99.08	66.26	1117
HSA-MIR-4464	98.95	67.73	820
HSA-MIR-4748	98.95	67.53	810
HSA-MIR-5011-3P	98.63	64.81	638
HSA-MIR-4252	98.45	66.37	987
HSA-MIR-1292-5P	96.74	62.14	238

Literature-anchored findings (GeneRIF, showing 10)

• The present data strongly suggest an important function of Ucma in the early phase of chondrocyte differentiation. (PMID:17707622)
• Ucma may be involved in the negative control of osteogenic differentiation of osteochondrogenic precursor cells (PMID:18156182)
• Gla-rich protein (GRP) is a new vitamin K-dependent protein that can bind calcium through Gla residues. (PMID:18836183)
• full exon resequencing of DNA samples from 17 chronic kidney disease patients (stage 5) and 121 healthy controls in a Swsedish population; the 138Thr > Ser polymorphism seems to be the only non-synonymous SNP found in the UCMA gene in a Swedish population (PMID:24409676)
• Data suggest that novel splice variants of GRP are expressed in cartilage and other tissues (i.e. GRP-F5, GRP-F6); GRP-F1 is predominant splice variant expressed in adult tissues particularly in cartilage of patients with osteoarthritis. (PMID:24867294)
• The study demonstrates the involvement of GRP in the two major molecular processes affecting osteoarthritis: mineralization and inflammation of articular tissue. (PMID:26337479)
• GRP might act as a novel molecular mediator linking inflammation and calcification events (PMID:28542410)
• Decreased levels of GRP and fetuin-A promote circulating calciprotein particle/extracellular vesicle mediated vascular calcification in chronic kidney disease. (PMID:29301790)
• Unique cartilage matrix-associated protein inhibits the migratory and invasive potential of triple-negative breast cancer. (PMID:32768190)
• Role of emerging vitamin Kdependent proteins: Growth arrestspecific protein 6, Glarich protein and periostin (Review). (PMID:33448308)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ucmab	ENSDARG00000005485
danio_rerio	ucmaa	ENSDARG00000027799
mus_musculus	Ucma	ENSMUSG00000026668
rattus_norvegicus	Ucma	ENSRNOG00000017987

Protein

Protein identifiers

Unique cartilage matrix-associated protein — Q8WVF2 (reviewed: Q8WVF2)

All UniProt accessions (5): A0A067XJP8, A0A067XJX6, A0A067XKV3, Q8WVF2, R4GMV7

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in the negative control of osteogenic differentiation of osteochondrogenic precursor cells in peripheral zones of fetal cartilage and at the cartilage-bone interface.

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Tissue specificity. Predominantly expressed in resting chondrocytes.

Post-translational modifications. Proteolytically cleaved by a furin-like convertase to generate a persistent C-terminal fragment found in almost the entire cartilage matrix, and affecting osteoblast differentiation. Sulfated on tyrosine residues.

Similarity. Belongs to the UCMA family.

RefSeq proteins (3): NP_001290047, NP_001290048, NP_660357* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR031386	UCMA	Family

Pfam: PF17085

UniProt features (5 total): chain 2, signal peptide 1, propeptide 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WVF2-F1	82.20	0.46

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8940973	RUNX2 regulates osteoblast differentiation

MSigDB gene sets: 232 (showing top): ATF_B, GOBP_SMAD_PROTEIN_SIGNAL_TRANSDUCTION, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_RESPIRATORY_GASEOUS_EXCHANGE_BY_RESPIRATORY_SYSTEM, GOBP_BEHAVIOR, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOCC_SECRETORY_GRANULE, GOBP_EMBRYONIC_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_NEGATIVE_REGULATION_OF_NERVOUS_SYSTEM_PROCESS, GOBP_OSTEOBLAST_DIFFERENTIATION, GOBP_HORMONE_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_BEHAVIOR, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY

GO Biological Process (5): osteoblast differentiation (GO:0001649), negative regulation of osteoblast differentiation (GO:0045668), embryonic skeletal system development (GO:0048706), negative regulation of SMAD protein signal transduction (GO:0060392), regulation of osteoblast differentiation (GO:0045667)

GO Molecular Function (2): BMP binding (GO:0036122), protein binding (GO:0005515)

GO Cellular Component (3): cytoplasm (GO:0005737), extracellular matrix (GO:0031012), extracellular region (GO:0005576)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RUNX2 regulates bone development	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
osteoblast differentiation	2
cellular anatomical structure	2
ossification	1
cell differentiation	1
negative regulation of cell differentiation	1
regulation of osteoblast differentiation	1
skeletal system development	1
chordate embryonic development	1
regulation of SMAD protein signal transduction	1
SMAD protein signal transduction	1
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
negative regulation of intracellular signal transduction	1
regulation of cell differentiation	1
cytokine binding	1
binding	1
intracellular anatomical structure	1
external encapsulating structure	1

Protein interactions and networks

STRING

392 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
UCMA	MGP	P08493	762
UCMA	GGCX	P38435	684
UCMA	AHSG	P02765	682
UCMA	PROS1	P07225	645
UCMA	PRRG1	O14668	595
UCMA	BGLAP	P02818	578
UCMA	GAS6	Q14393	576
UCMA	PRRG3	Q9BZD7	571
UCMA	PRRG2	O14669	521
UCMA	VKORC1	Q9BQB6	482
UCMA	FMOD	Q06828	452
UCMA	POSTN	Q15063	446
UCMA	PRRG4	Q9BZD6	436
UCMA	COL11A1	P12107	422
UCMA	LUM	P51884	383

IntAct

0 interactions, top by confidence:

BioGRID (1): UCMA (Two-hybrid)

ESM2 similar proteins: A0A023VZR2, A0A023W0B6, A0A023W0C3, A0A023W0V9, A0A023W0W9, A0A023W157, A0A023W163, A0A023W168, A0A3G1VU73, A0A3G1VU77, A0A3G1VU78, A0A3G1VU81, A0A3G1VU84, B9TQX1, B9TQX3, B9WZ56, E2AIS8, G7NYP9, O02036, O42143, O42144, P01362, P05305, P06308, P0CJ15, P0CJ16, P0CV00, P0DPY2, P0DQF5, P0DQG1, P10552, P17685, P17686, P21259, P41870, P41876, P49794, P61364, P61365, P61366

Diamond homologs: B9TQX1, B9TQX2, B9TQX3, B9TQX4, Q14BU0, Q28HK1, Q6NWB6, Q8WVF2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

54 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	47
Likely benign	3
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

498 predictions. Top by Δscore:

Variant	Effect	Δscore
10:13222199:CT:C	acceptor_gain	1.0000
10:13222201:C:CC	acceptor_gain	1.0000
10:13229608:TACC:T	donor_loss	1.0000
10:13229609:A:AC	donor_gain	1.0000
10:13229610:C:CC	donor_gain	1.0000
10:13229610:CCAT:C	donor_gain	1.0000
10:13229705:TTCCA:T	acceptor_gain	1.0000
10:13229706:TCCA:T	acceptor_gain	1.0000
10:13229707:CCA:C	acceptor_gain	1.0000
10:13229707:CCAC:C	acceptor_gain	1.0000
10:13229708:CA:C	acceptor_gain	1.0000
10:13229708:CAC:C	acceptor_gain	1.0000
10:13229710:C:CA	acceptor_loss	1.0000
10:13229710:C:CC	acceptor_gain	1.0000
10:13229711:T:C	acceptor_loss	1.0000
10:13229712:G:C	acceptor_gain	1.0000
10:13229712:G:GC	acceptor_gain	1.0000
10:13233801:C:CC	acceptor_gain	1.0000
10:13234199:A:AC	donor_gain	1.0000
10:13234200:C:CG	donor_gain	1.0000
10:13234200:CT:C	donor_gain	1.0000
10:13234200:CTAGA:C	donor_gain	1.0000
10:13222196:CTGCT:C	acceptor_gain	0.9900
10:13222197:TGCT:T	acceptor_gain	0.9900
10:13222201:C:CG	acceptor_loss	0.9900
10:13222202:T:A	acceptor_loss	0.9900
10:13229604:CTCTT:C	donor_loss	0.9900
10:13229609:AC:A	donor_gain	0.9900
10:13229609:ACCAT:A	donor_gain	0.9900
10:13229610:CC:C	donor_gain	0.9900

AlphaMissense

914 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:13222163:C:A	W119C	0.944
10:13222163:C:G	W119C	0.944
10:13233614:G:C	F48L	0.941
10:13233614:G:T	F48L	0.941
10:13233616:A:G	F48L	0.941
10:13233587:G:C	F57L	0.939
10:13233587:G:T	F57L	0.939
10:13233589:A:G	F57L	0.939
10:13222161:C:G	R120P	0.927
10:13222154:C:A	W122C	0.923
10:13222154:C:G	W122C	0.923
10:13222165:A:G	W119R	0.915
10:13222165:A:T	W119R	0.915
10:13233588:A:G	F57S	0.892
10:13233588:A:C	F57C	0.879
10:13222156:A:G	W122R	0.875
10:13222156:A:T	W122R	0.875
10:13222182:C:G	R113P	0.863
10:13229630:G:C	F100L	0.838
10:13229630:G:T	F100L	0.838
10:13229632:A:G	F100L	0.838
10:13233597:G:T	A54D	0.824
10:13233615:A:C	F48C	0.819
10:13229639:A:C	F97L	0.801
10:13229639:A:T	F97L	0.801
10:13229641:A:G	F97L	0.801
10:13233615:A:G	F48S	0.793
10:13234228:A:G	C11R	0.788
10:13222162:G:T	R120S	0.785
10:13222164:C:G	W119S	0.785

dbSNP variants (sampled 300 via entrez): RS1000027611 (10:13232372 A>C,G), RS1000345441 (10:13235623 T>C), RS1000417500 (10:13235072 T>A), RS1000691950 (10:13230235 G>A), RS1000760211 (10:13231529 G>A), RS1000992388 (10:13231441 T>C), RS1001296745 (10:13229097 A>C), RS1001317394 (10:13234435 C>T), RS1001322505 (10:13234073 C>T), RS1001387828 (10:13221358 A>G), RS1001676161 (10:13223818 C>T), RS1001749911 (10:13224049 C>T), RS1002043910 (10:13228759 G>A,C), RS1002088451 (10:13225333 T>A), RS1002992747 (10:13235265 C>T)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:148300

GenCC curated gene-disease

Mondo (1): keratoconus (MONDO:0015486)

Orphanet (2): OBSOLETE: Keratoconus (Orphanet:156071), NON RARE IN EUROPE: Isolated keratoconus (Orphanet:2335)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000563	Keratoconus

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST002783_166	Body mass index	4.000000e-08
GCST002783_220	Body mass index	9.000000e-09
GCST002783_566	Body mass index	1.000000e-06
GCST002991_2	Pancreatic cancer	3.000000e-07
GCST004495_133	BMI (adjusted for smoking behaviour)	4.000000e-08
GCST004495_134	BMI (adjusted for smoking behaviour)	1.000000e-06
GCST004497_105	Body mass index (joint analysis main effects and smoking interaction)	6.000000e-08
GCST004497_106	Body mass index (joint analysis main effects and smoking interaction)	3.000000e-06
GCST004499_41	BMI in non-smokers	6.000000e-08
GCST005434_3	Pancreatic cancer	3.000000e-08
GCST007203_15	Total cholesterol levels	2.000000e-06
GCST007235_4	Pancreatic ductal adenocarcinoma	2.000000e-06
GCST007923_17	Medication use (drugs used in diabetes)	3.000000e-09
GCST009379_222	Type 2 diabetes	8.000000e-09
GCST009612_2	Triglyceride levels x thiazide or thiazide-like diuretics use interaction	5.000000e-07
GCST009936_14	Venous thromboembolism	9.000000e-06
GCST010988_5	Adult body size	2.000000e-08
GCST90016669_16	Pancreas volume	3.000000e-09

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0004318	smoking behavior
EFO:0004574	total cholesterol measurement
EFO:0009924	Drugs used in diabetes use measurement
EFO:0004530	triglyceride measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D007640	Keratoconus	C11.204.627

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression	2
propionaldehyde	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Valproic Acid	increases methylation	1

Clinical trials (associated diseases)

279 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01485211	PHASE4	COMPLETED	Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Riboflavin
NCT02119039	PHASE4	COMPLETED	Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus
NCT03245853	PHASE4	COMPLETED	Epi-On Corneal Crosslinking for Keratoconus
NCT03429569	PHASE4	UNKNOWN	Cross-Linking ACcéléré Iontophorèse Confocal kératocONE
NCT04427956	PHASE4	COMPLETED	Corneal Crosslinking Treatment Study
NCT07474870	PHASE4	NOT_YET_RECRUITING	Outcomes of CTAK Surgery
NCT00371202	PHASE3	UNKNOWN	Comparison of Penetrating Keratoplasty and Deep Lamellar Keratoplasty With the Big Bubble Technique for Keratoconus
NCT00647699	PHASE3	COMPLETED	Corneal Collagen Cross-linking for Progressive Keratoconus
NCT00815256	PHASE3	UNKNOWN	Safety and Effectiveness of Collagen Cross Linking in Progressive Mild and Moderate Keratoconus
NCT00887900	PHASE3	COMPLETED	Deep Anterior Lamellar Keratoplasty (DALK)
NCT01112072	PHASE3	UNKNOWN	Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia
NCT01152541	PHASE3	UNKNOWN	Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin
NCT01190306	PHASE3	TERMINATED	Safety Study of the VEGA UV-A System to Treat Keratoconus
NCT01344187	PHASE3	COMPLETED	Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT01459679	PHASE3	TERMINATED	Safety & Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery
NCT01464268	PHASE3	UNKNOWN	Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia
NCT01604135	PHASE3	ACTIVE_NOT_RECRUITING	Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial
NCT01643226	PHASE3	COMPLETED	Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT01672814	PHASE3	COMPLETED	Microwave Treatment and Corneal Collagen Crosslinking for Keratoconus
NCT01682993	PHASE3	TERMINATED	Corneal Cross Linking and Topography Guided Excimer Laser Treatment
NCT01972854	PHASE3	TERMINATED	Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT02613780	PHASE3	UNKNOWN	Refractive Treatment of Early Keratoconus
NCT02638376	PHASE3	UNKNOWN	Evaluating the Safety and Efficacy of the KXL System for Corneal Collagen Cross-Linking in Eyes Having Keratoconus
NCT03080077	PHASE3	UNKNOWN	Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia
NCT03187912	PHASE3	COMPLETED	Accelerated Corneal Cross-linking With Different Riboflavin Solutions
NCT03442751	PHASE3	COMPLETED	Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
NCT03858036	PHASE3	UNKNOWN	Corneal Collagen Cross-Linking (CXL) Performed With Epi-ON Versus Epi-OFF in Eyes With Keratoconus and Other Corneal Ectatic Disorders
NCT04897503	PHASE3	UNKNOWN	Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose
NCT04905108	PHASE3	UNKNOWN	Transepithelial (Epi-on) Corneal Collagen Crosslinking to Treat Keratoconus and Corneal Ectasia
NCT05027295	PHASE3	UNKNOWN	Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light
NCT06100939	PHASE3	ACTIVE_NOT_RECRUITING	Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
NCT06100952	PHASE3	ACTIVE_NOT_RECRUITING	Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus
NCT06450470	PHASE3	RECRUITING	Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus
NCT06601101	PHASE3	RECRUITING	Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus
NCT07124910	PHASE3	RECRUITING	Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
NCT07135167	PHASE3	RECRUITING	Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome
NCT00409955	PHASE2	COMPLETED	Lamellar Transplant With Lyophilized Corneas
NCT00925327	PHASE2	UNKNOWN	Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus
NCT01143389	PHASE2	COMPLETED	Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
NCT01181219	PHASE2	COMPLETED	Transepithelial Corneal Collagen Cross-linking (CXL) in Treatment of Keratoconus